Скачать с ютуб CAR-T therapy for R/R aggressive B-cell NHL в хорошем качестве

CAR-T therapy for R/R aggressive B-cell NHL

Michael Bishop, MD, University of Chicago, Chicago, IL, discusses the use of chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (NHL), highlighting key clinical trials. CAR-T therapy has been effective in patients who have progressed after multiple lines of therapy but there is less data for patients with primary refractory disease after frontline therapy. Three prospective Phase III clinical trials (ZUMA-7, NCT03391466; TRANSFORM, NCT03575351; BELINDA, NCT03570892) are currently comparing high-dose chemotherapy and autologous stem cell transplantation with CAR-T therapy as a second-line treatment in patients with R/R B-cell NHL. Preliminary data has shown improvements in event-free survival for patients receiving CAR-T therapy over standard of care for two out of the three trials. A closer look at the trial design of each of these trials is essential to assess whether they can be compared to one another. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.